l-Arginine metabolism in cardiovascular and renal tissue from hyper- and hypothyroid rats

Experimental Biology and Medicine

Volumn 241, Issue 5, 2016, Pages 550-556

  Rodríguez Gómez, Isabel ^a,c   Moliz, Juan N ^b   Quesada, Andrés ^c,d   Montoro Molina, Sebastian ^c,d   Vargas Tendero, Pablo ^a,c   Osuna, Antonio ^a,c   Wangensteen, Rosemary ^c   Vargas, Félix ^a,c  

^a Granada Health Research Institute ibs GRANADA   (Spain)

^b Departamento de Fisiología   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

Author keywords

aorta; heart kidney; Hyperthyroidism; hypothyroidism; l arginine metabolism; rat

Indexed keywords

ARGINASE; ARGININE; ARGININE DECARBOXYLASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIOTHYRONINE; NEURONAL NITRIC OXIDE SYNTHASE; ORNITHINE DECARBOXYLASE; ORNITHINE OXOACID AMINOTRANSFERASE; PROLINE; SPERMIDINE; THIAMAZOLE; THYROTROPIN; THYROXINE; THYROID HORMONE;

AMINO ACID METABOLISM; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR TISSUE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY PARENCHYMA; MALE; MASS SPECTROMETRY; NONHUMAN; PLETHYSMOGRAPHY; RADIOIMMUNOASSAY; RAT; ANIMAL; AORTA; CARDIAC MUSCLE; DRUG EFFECTS; KIDNEY; LIVER; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; AORTA; ARGININE; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY; LIVER; MALE; METABOLIC NETWORKS AND PATHWAYS; MYOCARDIUM; RATS, WISTAR; THYROID HORMONES;

EID: 84958720262     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370215619042     Document Type: Article

References (35)

1. S.Moncada. Nitric oxide in the vasculature: physiology and pathophysiology. Ann NY Acad Sci1997; 811: 60–7.
2. C.ThorupA.E.Persson. Nitric oxide and renal blood pressure regulation. Curr Opin Nephrol Hypertens1998; 7: 197–202.
3. L.RaijC.Bayli. Glomerular actions of nitric oxide. Kidney Int1995; 48: 20–32.
4. C.P.JenkinsonW.W.GrodyS.D.Cederbaum. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol1996; 114: 107–32.
5. S.M.MorrisJrD.BhamidipatiD.Kepka-Lenhart. Human type II arginase: sequence analysis and tissue-specific expression. Gene1997; 193: 157–61.
6. O.ShiD.Kepka-LenhartS.M.MorrisJrW.E.O’Brien. Structure of the murine arginase II gene. Mamm Genome1998; 9: 822–4.
7. G.M.BugaR.SinghS.PervinN.E.RogersD.A.SchmitzC.P.JenkinsonS.D.CederbaumL.J.Ignarro. Arginase activity in endothelial cells: inhibition by N[omega]-hydroxy-l-arginine during high-output NO production. Am J Physiol1996; 271: H1988–98.
8. L.J.IgnarroG.BugaL.H.WieP.M.BauerG.WuP.del Soldato. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA2001; 98: 4202–42089.
9. G.WuS.M.MorrisJr. Arginine metabolism: nitric oxide and beyond. Biochem J1998; 336: 1–17.
10. V.E.Shih. Regulation of ornithine metabolism. Enzyme1981; 26: 254–8.
11. A.A.ReyesI.E.KarlS.Klahr. Role of arginine in health and in renal disease. Am J Physiol1994; 267: F331–46.
12. C.L.BerryK.J.Henrichs. Morphometric investigation of hypertrophy in the arteries of DOCA-hypertensive rats. J Physiol1982; 136: 85–94.
13. J.MorrisseyR.McCrackenS.IshidoyaS.Klahr. Partial cloning and characterization of an arginine decarboxylase in the kidney. Kidney Int1995; 47: 1458–61.
14. I.Rodríguez-GómezJ.SainzR.WangensteenJ.M.MorenoJ.DuarteA.OsunaF.Vargas. Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension2003; 42: 220–5.
15. A.QuesadaJ.SainzR.WangensteenI.Rodriguez-GomezF.VargasA.Osuna. Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. Eur J Endocrinol2002; 147: 117–22.
16. I.Rodríguez-GómezR.WangensteenJ.M.MorenoV.ChamorroA.OsunaF.Vargas. Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats. Am J Physiol Endocrinol Metab2005; 288: E1252–7.
17. F.VargasM.J.BazJ.D.LunaJ.AndradeE.JodarJ.M.Haro. Urinary excretion of digoxin-like immunoreactive factor and arginine vasopressin in hyper-and hypothyroid rats. Clin Sci1991; 81: 471–6.
18. F.VargasN.AtuchaJ.M.SabioT.QuesadaJ.García-Estañ. Pressure–diuresis–natriuresis response in hyper- and hypothyroid rats. Clin Sci1994; 87: 323–8.
19. S.N.DhanakotiJ.T.BrosnanG.R.HerzbergM.E.Brosnan. Renal arginine synthesis: studies in vitro and in vivo. Am J Physiol1990; 259: E437–42.
20. F.VargasJ.M.MorenoI.Rodríguez-GómezR.WangensteenM.Alvarez-GuerraA.OsunaJ.García-Estañ. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol2006; 154: 1–17.
21. I.Rodríguez-GómezI.BanegasR.WangensteenA.QuesadaR.JimenezM.Gómez-MoralesF.O’ValleJ.DuarteF.Vargas. Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats. J Endocrinol2012; 216: 1–10.
22. F.VargasA.Fernández-RivasJ.García EstañC.García del Río. Endothelium-dependent and endothelium-independent vasodilation in hyperthyroid and hypothyroid rats. Pharmacology1995; 51: 308–14.
23. N.ChakrabartiA.K.Ray. Rise of intrasynaptosomal Ca2+ level and activation of nitric oxide synthase in adult rat cerebral cortex pretreated with 3-5-30-L-triiodothyronine. Neuropsychopharmacology2000; 22: 36–41.
24. N.D.VaziriN.ZhenminF.Oveisi. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension1998; 31: 1248–54.
25. F.VargasI.Rodriguez-GómezP.Vargas-TenderoE.JiménezM.Montiel. The renin–angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. J Endocrinol2012; 213: 25–36.
26. G.SinghE.B.ThompsonA.Gulati. Altered endothelin 1 concentration in brain and peripheral regions during thyroid dysfunction. Pharmacology1994; 49: 184–91.
27. A.PopoloS.AdessoA.PintoG.AutoreS.Marzocco. l-Arginine and its metabolites in kidney and cardiovascular disease. Amino Acids2014; 46: 2271–86.
28. Rodríguez-Gómez I, Moreno JM, Jimenez R, Quesada A, Montoro-Molina S, Vargas-Tendero P, Wangensteen R, Vargas F. Effects of arginase inhibition in hypertensive hyperthyroid rats. Am J Hypertens (doi:10.1093/ajh/hpv049)
29. A.E.PeggH.Hibasami. Polyamine metabolism during cardiac hypertrophy. Am J Physiol1980; 239: E372–8.
30. Y.LinX.ZhangL.WangY.ZhaoH.LiW.XiaoC.XuJ.Liu. Polyamine depletion attenuates isoproterenol-induced hypertrophy and endoplasmic reticulum stress in cardiomyocytes. Cell Physiol Biochem2014; 34: 1455–65.
31. J.C.CubriaR.RegueraR.Balana-FouceC.OrdoñezD.Ordoñez. Polyamine-mediated heart hypertrophy induced by clenbuterol in the mouse. J Pharm Pharmacol1998; 50: 91–6.
32. P.KucharzewskaJ.E.WelchK.J.SvenssonM.Belting. Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells. Exp Cell Res2010; 316: 2683–91.
33. S.A.V.RaghavanM.Dikshit. Vascular regulation by the l-arginine metabolites, nitric oxide and agmatine. Pharmacol Res2004; 49: 397–414.
34. H.HayakawaY.HirataE.SuzukiK.KimuraK.KikuchiT.NaganoM.HirobeM.Omata. Long-term administration of l-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate-salt hypertensive rats. Hypertension1994; 23: 752–6.
35. G.R.AbreuH.A.Futuro-NetoA.M.CabralE.C.Vasquez. L-arginine restores the effect of ouabain on baroreceptor activity and prevents hypertension. Hypertension1999; 34: 729–32.